Solventum (NYSE:SOLV) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Solventum (NYSE:SOLV) from a buy rating to a hold rating in a research note published on Saturday,Wall Street Zen reports.

Several other research analysts have also issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 target price (up from $105.00) on shares of Solventum in a research report on Friday. Weiss Ratings raised Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. KeyCorp boosted their price target on Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Mizuho set a $113.00 price target on Solventum in a research note on Thursday, August 6th. Finally, UBS Group upped their price objective on shares of Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Ten equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Solventum currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.27.

Solventum Trading Up 0.1%

NYSE:SOLV opened at $90.51 on Friday. The stock has a market capitalization of $15.41 billion, a price-to-earnings ratio of 12.59, a PEG ratio of 1.30 and a beta of 0.69. Solventum has a 52 week low of $62.38 and a 52 week high of $94.16. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The firm has a 50 day moving average of $87.72 and a 200 day moving average of $78.75.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.11. The business had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.93 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.50 earnings per share. As a group, sell-side analysts anticipate that Solventum will post 7.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Solventum

Large investors have recently made changes to their positions in the stock. Laurel Wealth Advisors LLC purchased a new position in Solventum during the third quarter worth approximately $29,000. Clearstead Trust LLC increased its position in shares of Solventum by 61.0% in the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after buying an additional 150 shares in the last quarter. JNBA Financial Advisors increased its position in shares of Solventum by 71.9% in the second quarter. JNBA Financial Advisors now owns 507 shares of the company’s stock valued at $39,000 after buying an additional 212 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of Solventum during the 2nd quarter worth approximately $47,000. Finally, Ancora Advisors LLC acquired a new position in shares of Solventum during the 2nd quarter worth approximately $56,000.

About Solventum

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024.

The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Solventum serves customers in the United States and international markets.